JPRN-UMIN000048523尚未招募未知
Effect of tofogliflozin on glycemic fluctuation in patients with type 2 diabetes with non-alcoholic fatty liver disease (NAFLD) - Effect of tofogliflozin on glycemic fluctuation in patients with type 2 diabetes with non-alcoholic fatty liver disease (NAFLD)
Minami Osaka Hospital0 个研究点目标入组 24 人开始时间: 2022年8月4日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients with hypersensitivity to tofogliflozin 2.Patients with contraindications to tofogliflozin 3.Patients with severe renal dysfunction eGFR oh less than 30 or end stage renal disease during dialysis 4.Patients with autoimmune hepatitis, viral liver disease, drug induced fatty liver, primary biliary cirrhosis, and metabolic liver disease 5.Patients who have been treated with SGLT2 inhibitor, GLP1 receptor agonist, and thiazolidine within 3 months before enrollment 6.Patients who the doctor deems inappropriate for participation in this study
研究者
相似试验
已完成
不适用
Study of the effect of tofogliflozin on glucose and lipid metabolism abnormality after the test meal loading.JPRN-UMIN000015778Kanazawa Medical University10
招募中
不适用
The effect of SGLT2 inhibitor tofogliflozin on glycemic daily variation by blood glucose using CGMs in patient with type 2 diabetes.JPRN-UMIN000025454Dokkyo Medical University Department of Endocrinology and Metabolism20
已完成
不适用
Effect on Insulin Resistance in Tofogliflozin-treated Japanese Type 2 diabetic patientsType 2 diabetesJPRN-UMIN000017006Matsuba Medical Clinic15
进行中（未招募）
1 期
Effect of the antidiabetic drug dapagliflozin on the coronary function in type 2 diabetic patients.EUCTR2021-003310-39-BECHU Saint Pierre100
已完成
不适用
The effect of Tofogliflozin (SGLT2 inhibitor) on endogenous glucose production and insulin clearance.JPRN-jRCTs031180117Tamura Yoshifumi12